Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Extended Half-Life Clotting Factors Cut Infusions, Hike Prices

Publish date:: May 1, 2019

Key clinical point: Extended half-life clotting factors cut infusion frequency but cost much more.

Major finding: Extended half-life factor IX halved the number infusions, but increased the cost from $697,497 to more than $1 million in a year.

Study details: The study examined usage patterns in nearly 8,000 patients over 18 months.

Disclosures: The study was funded HTRS/ATHN Dataset Research Engagement and a DREAM Award from the Hemostasis and Thrombosis Research Society. Dr. Croteau reported consulting for Bayer, Bioverativ, Biomarin, CSL-Behring, and other companies.

Citation:

Croteau SE et al. Haemophilia. 2019. doi: 10.1111/hae.13758.

This Week's Must Reads

AGA releases BRCA risk guidance,

Oral difelikefalin quells severe chronic kidney disease–associated itch,

Children rarely transmit SARS-CoV-2 within households,

Transitioning regimen may prolong proteasome inhibitor–based therapy for MM,

Brensocatib reduced bronchiectasis exacerbations,

Must Reads in Hematology

Transitioning regimen may prolong proteasome inhibitor–based therapy for MM,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,

Subcutaneous hep A vaccination as effective as intramuscular for bleeding disorder patients,